Teva Launches Generic Epzicom Tablets In US

(RTTNews) - Teva Pharmaceutical Industries Ltd., (TEVA) announced the launch of a generic equivalent of Epzicom or abacavir and lamivudine tablets, 600 mg/300 mg, in the United States. Abacavir and lamivudine tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. When used in combination with other antiretroviral medicines used to treat HIV-1 infection, abacavir and lamivudine tablets may help to reduce the amount of HIV-1 in affected patients' blood (viral load), and increase the number of CD4+ (T) cells in affected patients' blood to help fight off other infections.

Reducing the amount of HIV-1 and increasing the CD4+ (T) cells in the blood may help improve affected patients' immune systems, and may reduce the risk of death or getting infections that can happen when a patient's immune system is weak (opportunistic infections).Abacavir and lamivudine tablets are not a cure for HIV or AIDS.

Epzicom (abacavir and lamivudine) tablets had annual sales of approximately $449 million in the U.S. according to IMS data as of July 2016.